About the cobas HPV Test on the cobas 4800 platform
Roche's cobas HPV Test simultaneously detects 12 high-risk HPV types (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) as a pooled result, as well as HPV genotypes 16 and 18 individually. Roche received FDA approval on the cobas HPV Test and in April 2011 and launched the cobas HPV Test in countries that accept CE Mark in 2009.
Due to key features such as the "load and go" facility for reagents, The cobas HPV test is easy and simple to use with minimal hands-on and maximum walkaway time whilst providing high throughput capabilities and has the flexibility to meet smaller throughput requirements.
About Human Papillomavirus and Cervical Cancer
Persistent infection with human papillomavirus is the cause of cervical cancer in women, with HPV being found in 99.7 per cent of cervical cancers worldwide. Of the more than 118 different types of HPV, the cobas® HPV Test identifies the 14 high-risk types associated with the development of cervical cancer and its precursor lesions. HPV types 16 and 18 have been identified as the highest risk genotypes, detected in approximately 70 per cent of cervical cancers. Nucleic acid (DNA) testing is a sensitive and non-invasive method for determining the presence of HPV infection.
The World Health Organization estimates there are 470,000 new cases of cervical cancer annually.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differ
Copyright©2010 PR Newswire.
All rights reserved